Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril

Journal of Human Hypertension

Volumn 11, Issue 8, 1997, Pages 483-489

  Black, H R ^a   Graff, A ^b   Shute, D ^c   Stoltz, R ^d   Ruff, D ^b   Levine, J ^b   Shi, Y ^e   Mallows, S ^e  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Metropolitan Clinic ^*

^c Metropolitan Clinic   (United States)

^d GFI Pharmaceutical Services Inc   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACE; Angiotensin II receptor antagonist; Angiotensin converting enzyme inhibitor; Essential hypertension; Lisinopril; Valsartan

Indexed keywords

ANGIOTENSIN II ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RASH; REGRESSION ANALYSIS; SINUSITIS; SITTING; SYSTOLIC BLOOD PRESSURE; TABLET; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VIRUS INFECTION; VOMITING;

EID: 0030846109     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000482     Document Type: Article

References (16)

1. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Brenner BM, Laragh JH), (eds). Hypertension. Raven Press Ltd: New York, 1990, pp 1287-1319.
2. Sassano P et al. Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension: Evaluation by two methods of blood pressure measurement. Am J Med 1984; 20 Aug: 18-22.
3. Frishman WH, Goldberger J, Sherman D. Enalapril, hydrocholorothiazide, and combination therapy in patients with moderate hypertension. J Clin Hypertens 1987; 3: 520-527.
4. Kaufman MP, Coleridge HM, Coleridge JCG, Baker DG. Bradykinin stimulates afferent vagal C-fibers in intrapulmonary airways of dogs. Am Physiol Soc 1980; 48: 511-517.
5. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Int Med 1992; 117: 234-242.
6. Morice AH, Brown MJ, Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1989; 13: S59-S62.
7. Semple PF, Herd GW. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. N Engl J Med 1986; 314: 61.
8. Webb D et al. Enalapril induced cough. Lancet 1986; 2: 1094.
9. Foote EF, Halstenson CE. New therapeutic agents in the management of hypertension: angiotensin II receptor antagonists and renin inhibitors. Ann Pharmacother 1993; 27: 1495-1503.
10. Tikkanen I, Omvik P, Jensen HA, Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-1351.
11. 1993 Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. Clin Exper Hypertens 1993; 15(6): 1363-1395.
12. Müller P et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-245.
13. Oparil S et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810.
14. Flesch G, Müller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997; 52: 115-120.
15. Waldmeier F et al. The metabolism of valsartan in man. Xenobiotica 1997; 27: 59-71.
16. Lipsitz L. Orthostatic hypotension in the elderly. NEJM 1989; 321: 952-957.